newsfilter
← Latest News
GlobeNewswire·

Quell® Demonstrates Encouraging Clinical Trial Results in Chemotherapy Induced Peripheral Neuropathy (CIPN)

WOBURN, Mass., May 31, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (NASDAQ:NURO) noted publication of an abstract describing partial results from a NIH-funded, multi-site randomized controlled trial of Quell titled